UV Spectrophotometric Method Development and Validation of Darunavir in bulk and Solid Dosage Form

Tegeli, Varsha; Birajdar, Avinash; Matole, Vinod

doi:10.52711/0974-360x.2021.00567

Cited by 9 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proposed approach was demonstrated to be accurate as the average %RSD values for the intraday and interday precision studies were found to be 0.50% and 0.88%, respectively Table 3 and Table 4 14 .…”

Section: Precisionmentioning

confidence: 94%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

Climbazole is a topical antifungal agent commonly used to treat human fungal skin infections such as dandruff and eczema. The goal of research work was to develop and validate a simple, precise, quick, and highly efficient UV spectrophotometric approach for quantifying Climbazole in bulk and shampoo dosage form. The quantification was completed using a twin beam UV spectrophotometer at 222 nm and ethanol (99.9%) as the solvent for the estimate. The Climbazole calibration curve exhibit strong correlation coefficient (R 2 =0.9938) and high linearity in the range of 5-25 µg/ml concentrations. The accuracy was found to be between 98.21%-99.83%. The accuracy of the approach was proved by the percent relative standard deviation being less than 2.0%. It was observed that the intraday and interday precision found within acceptable ranges. The method's sensitivity was assessed using the detection limit and quantification limit, which were discovered to be 2.37 µg/ml and 7.20 µg/ml, respectively. In this paper, we introduce a UV-spectrophotometric technique for investigating Climbazole using ethanol as solvent. The suggested method demonstrated excellent selectivity, specificity, and linearity in accordance with ICH Q2 (R1) requirements. Also, marketed pharmaceutical formulations were used to show the developed approach's efficiency and a high recovery rate. It is obvious that the suggested method will serve as a normative approach for the regular testing of Climbazole in pharmaceutical formulations and bulk dosage forms.

show abstract

Section: Precisionmentioning

confidence: 94%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

show abstract

“…On the other hand, D.V is the second generation non-peptidic peptidomimetic PI and antiretroviral drug that requires a high therapeutic dose, to deal with the problems such as severe side effects and drug toxicities [4,5]. D.V is used orally with ritonavir and other medicated combinations to treat and prevent HIV/AIDS [6].…”

Section: Introductionmentioning

confidence: 99%

Designing of drug imprinted polymeric microcryogels for controlled release of Darunavir

Şafak,

Çalışır,

Bakhshpour-Yucel

et al. 2024

Chem. Pap.

View full text Add to dashboard Cite

Darunavir (D.V) is a pivotal antiretroviral medication designed to combat viruses with prolonged treatment requirements, notably gaining recognition as one of the primary choices for treating AIDS, a disease caused by the human immunode ciency virus (HIV). Bio polymeric materials like microcryogels become the center of attention in most research areas such as controlled release systems. These systems offer the advantage of precise drug administration, ensuring effective therapeutic outcomes through the delivery of speci c drug doses. Microcryogels, characterized by their super macroporous, elastic, and spongy morphology, have emerged as a focal point in biomedical applications, particularly when combined with molecularly imprinted polymers (MIPs). In this study, the controlled release and kinetics studies of the D.V were investigated with the D.V imprinted poly (2-hydroxyethyl methacrylate) (pHEMA) based microcryogels. D.V imprinted pHEMA microcryogels with different cross-linker ratios and different loaded drugs were prepared for studies of in vitro release of D.V scanning electron microscopy (SEM), Brunauer-Emmett-Teller (BET) and Fourier transform infrared spectroscopy (FTIR) methods have been considered suitable for the characterization of cryogels that have been designed and whose sensitivity has been enhanced by molecular imprinting. Cytotoxicity of D.V imprinted microcryogels was also inspected using mouse broblast cell line L929. The comprehensive analysis results underscore the potential of these meticulously designed microcryogels, showcasing their utility in medical applications.Notably, these microcryogels exhibited controlled drug release, with e ciency levels of up to 85% and a sustained release duration of 40 hours, positioning them as a valuable option for advanced drug delivery systems in the medical eld.

show abstract

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update

Mia,

Howlader,

Akter

et al. 2024

Clin Med�Insights�Pathol

View full text Add to dashboard Cite

The COVID-19 pandemic-led worldwide healthcare crisis necessitates prompt societal, ecological, and medical efforts to stop or reduce the rising number of fatalities. Numerous mRNA based vaccines and vaccines for viral vectors have been licensed for use in emergencies which showed 90% to 95% efficacy in preventing SARS-CoV-2 infection. However, safety issues, vaccine reluctance, and skepticism remain major concerns for making mass vaccination a successful approach to treat COVID-19. Hence, alternative therapeutics is needed for eradicating the global burden of COVID-19 from developed and low-resource countries. Repurposing current medications and drug candidates could be a more viable option for treating SARS-CoV-2 as these therapies have previously passed a number of significant checkpoints for drug development and patient care. Besides vaccines, this review focused on the potential usage of alternative therapeutic agents including antiviral, antiparasitic, and antibacterial drugs, protease inhibitors, neuraminidase inhibitors, and monoclonal antibodies that are currently undergoing preclinical and clinical investigations to assess their effectiveness and safety in the treatment of COVID-19. Among the repurposed drugs, remdesivir is considered as the most promising agent, while favipiravir, molnupiravir, paxlovid, and lopinavir/ritonavir exhibited improved therapeutic effects in terms of elimination of viruses. However, the outcomes of treatment with oseltamivir, umifenovir, disulfiram, teicoplanin, and ivermectin were not significant. It is noteworthy that combining multiple drugs as therapy showcases impressive effectiveness in managing individuals with COVID-19. Tocilizumab is presently employed for the treatment of patients who exhibit COVID-19-related pneumonia. Numerous antiviral drugs such as galidesivir, griffithsin, and thapsigargin are under clinical trials which could be promising for treating COVID-19 individuals with severe symptoms. Supportive treatment for patients of COVID-19 may involve the use of corticosteroids, convalescent plasma, stem cells, pooled antibodies, vitamins, and natural substances. This study provides an updated progress in SARS-CoV-2 medications and a crucial guide for inventing novel interventions against COVID-19.

show abstract

UV Spectrophotometric Method Development and Validation of Darunavir in bulk and Solid Dosage Form

Cited by 9 publications

References 3 publications

Untitled

Untitled

Designing of drug imprinted polymeric microcryogels for controlled release of Darunavir

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update

Contact Info

Product

Resources

About